Johnson & Johnson - Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
Elanco Animal Health Inc. - Elanco Investor Day Defines New Era as Sustainable Growth Company
Elanco Investor Day Defines New Era as Sustainable Growth Company
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
Lillys Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years